Gestational choriocarcinoma
© IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ..
Gestational choriocarcinoma accounts for 5% of gestational trophoblastic neoplasms. Approximately 50%, 25%, and 25% of gestational choriocarcinoma occur after molar pregnancies, term pregnancies, and other gestational events, respectively. The FIGO scoring system categorizes patients into low (score 0 to 6) and high risk (score 7 or more) choriocarcinoma. Single-agent and multi-agent chemotherapy are used in low- and high-risk patients, respectively. Chemotherapy for localized disease has a goal of eradication of disease without surgery and is associated with favorable prognosis and fertility preservation. Most patients with gestational choriocarcinoma are cured with chemotherapy; however, some (<5.0%) will die as a result of multi-drug resistance, underscoring the need for novel approaches in this group of patients. Although there are limited data due to its rarity, the treatment response with immunotherapy is high, ranging between 50-70%. Novel combinations of immune checkpoint inhibitors with targeted therapies (including VEGFR-2 inhibitors) are under evaluation. PD-L1 inhibitors are considered a potential important opportunity for chemo-resistant patients, and to replace or de-escalate chemotherapy to avoid or minimize chemotherapy toxicity. In this review, the Rare Tumor Working Group and the European Organization for Research and Treatment of Cancer evaluated the current landscape and further perspective in the management of patients diagnosed with gestational choriocarcinoma.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society - 33(2023), 10 vom: 02. Okt., Seite 1504-1514 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Genital Neoplasms, Female |
|---|
| Anmerkungen: |
Date Completed 04.10.2023 Date Revised 04.10.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/ijgc-2023-004704 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362547343 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362547343 | ||
| 003 | DE-627 | ||
| 005 | 20231226091451.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/ijgc-2023-004704 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1208.xml |
| 035 | |a (DE-627)NLM362547343 | ||
| 035 | |a (NLM)37758451 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bogani, Giorgio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Gestational choriocarcinoma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.10.2023 | ||
| 500 | |a Date Revised 04.10.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a Gestational choriocarcinoma accounts for 5% of gestational trophoblastic neoplasms. Approximately 50%, 25%, and 25% of gestational choriocarcinoma occur after molar pregnancies, term pregnancies, and other gestational events, respectively. The FIGO scoring system categorizes patients into low (score 0 to 6) and high risk (score 7 or more) choriocarcinoma. Single-agent and multi-agent chemotherapy are used in low- and high-risk patients, respectively. Chemotherapy for localized disease has a goal of eradication of disease without surgery and is associated with favorable prognosis and fertility preservation. Most patients with gestational choriocarcinoma are cured with chemotherapy; however, some (<5.0%) will die as a result of multi-drug resistance, underscoring the need for novel approaches in this group of patients. Although there are limited data due to its rarity, the treatment response with immunotherapy is high, ranging between 50-70%. Novel combinations of immune checkpoint inhibitors with targeted therapies (including VEGFR-2 inhibitors) are under evaluation. PD-L1 inhibitors are considered a potential important opportunity for chemo-resistant patients, and to replace or de-escalate chemotherapy to avoid or minimize chemotherapy toxicity. In this review, the Rare Tumor Working Group and the European Organization for Research and Treatment of Cancer evaluated the current landscape and further perspective in the management of patients diagnosed with gestational choriocarcinoma | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Genital Neoplasms, Female | |
| 650 | 4 | |a Gestational Trophoblastic Disease | |
| 700 | 1 | |a Ray-Coquard, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Mutch, David |e verfasserin |4 aut | |
| 700 | 1 | |a Vergote, Ignace |e verfasserin |4 aut | |
| 700 | 1 | |a Ramirez, Pedro T |e verfasserin |4 aut | |
| 700 | 1 | |a Prat, Jaime |e verfasserin |4 aut | |
| 700 | 1 | |a Concin, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Ngoi, Natalie Yan Li |e verfasserin |4 aut | |
| 700 | 1 | |a Coleman, Robert L |e verfasserin |4 aut | |
| 700 | 1 | |a Enomoto, Takayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Takehara, Kazuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Denys, Hannelore |e verfasserin |4 aut | |
| 700 | 1 | |a Lorusso, Domenica |e verfasserin |4 aut | |
| 700 | 1 | |a Takano, Masashi |e verfasserin |4 aut | |
| 700 | 1 | |a Sagae, Satoru |e verfasserin |4 aut | |
| 700 | 1 | |a Wimberger, Pauline |e verfasserin |4 aut | |
| 700 | 1 | |a Segev, Yakir |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Se Ik |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Jae-Weon |e verfasserin |4 aut | |
| 700 | 1 | |a Herrera, Fernanda |e verfasserin |4 aut | |
| 700 | 1 | |a Mariani, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Brooks, Rebecca A |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, David |e verfasserin |4 aut | |
| 700 | 1 | |a Paolini, Biagio |e verfasserin |4 aut | |
| 700 | 1 | |a Chiappa, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Longo, Mariangela |e verfasserin |4 aut | |
| 700 | 1 | |a Raspagliesi, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Benedetti Panici, Pierluigi |e verfasserin |4 aut | |
| 700 | 1 | |a Di Donato, Violante |e verfasserin |4 aut | |
| 700 | 1 | |a Caruso, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Colombo, Nicoletta |e verfasserin |4 aut | |
| 700 | 1 | |a Pignata, Sandro |e verfasserin |4 aut | |
| 700 | 1 | |a Zannoni, Gianfranco |e verfasserin |4 aut | |
| 700 | 1 | |a Scambia, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Monk, Bradley J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of gynecological cancer : official journal of the International Gynecological Cancer Society |d 1992 |g 33(2023), 10 vom: 02. Okt., Seite 1504-1514 |w (DE-627)NLM090676645 |x 1525-1438 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2023 |g number:10 |g day:02 |g month:10 |g pages:1504-1514 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/ijgc-2023-004704 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2023 |e 10 |b 02 |c 10 |h 1504-1514 | ||